Introduction
One of the more prevalent afflictions in Southeast Asia is nasopharyngeal carcinoma (NPC), a unique type of head and neck cancer. 1, 2 Radiotherapy is the main treatment for NPC, and in recent years, intensity-modulated radiotherapy (IMRT) has been widely used, thus improving the clinical management of NPC, especially the local control (LC) rate. Treatment failure and disease progression of NPC have shifted from local recurrence and distant metastasis (DM) following 2-dimensional radiotherapy (2DRT) to DM following IMRT.
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Tang et al more severe anemia was associated with poorer radiotherapy effects. These and other factors highlight the need to develop new therapeutic approaches for improving the prognosis of patients with NPC.
A number of epidemiological studies have investigated a causal link between cancer incidence and lipid levels. Studies have shown that increased dietary fat or cholesterol is correlated with an increased risk of certain malignancies, including lung, 8 colorectal, 9 breast, 10 and prostate cancers. 11 However, few studies have explored the causal and mechanistic associations between increased lipid levels and cancer behavior. Hyperlipidemia might favor lymph node metastasis in men with early gastric cancer. 12 High levels of lowdensity lipoprotein cholesterol (LDL-C) can induce breast cancer proliferation and invasion and promote breast cancer progression. 13 LDL-C is a significant predictor of survival in women with epithelial ovarian cancer. 14 Pretreatment LDL-C levels may serve as a prognostic factor for cancer patients. In this study, we retrospectively investigated the correlation between pretreatment LDL-C levels and long-term outcomes in patients with NPC.
Patients and methods ethics statement
This study was approved by the Institutional Review Board of the Zhejiang Province Cancer Centre. Written informed consent was obtained from all patients in accordance with the Declaration of Helsinki.
Patients
From January 2008 to December 2011, 935 patients with NPC were treated with IMRT. This cohort included 658 male and 277 female patients aged 11-70 years (median, 49 years). Of the 935 NPC patients, 64 and 871 had World Health Organization pathological type II and III, respectively. The clinical staging features of these cancers (stage, T stage, and N stage) are reported in Table 1 . The mean pretreatment LDL-C level for all patients was 2.72 mmol/L (range: 1.05-5.92 mmol/L). There were 816 patients in the normal LDL-C group (#3.64 mmol/L) and 119 patients in the elevated LDL-C group (.3.64 mmol/L). The clinical data of the two groups are shown in Table 1 . In this cohort study, 25 (3.1%) and 28 (23.5%) patients were statin users among the NPC patients with normal and elevated LDL-C levels, respectively. One statin user with normal LDL-C levels died of cerebral infarction 56 months after treatment; one non-statin user with elevated LDL-C levels was treated with aspirin enteric-coated tablets to prevent thrombosis, a beta blocker to protect heart function, and statins to lower blood lipids because of coronary heart disease that appeared 25 months or more after treatment.
radiotherapy method
All patients underwent radical IMRT. The prescription dose of the gross tumor volume of the nasopharynx, metastatic lymph nodes, clinical target volume, and prophylactic irradiating region were 68-72 Gy, 60-66 Gy, 60 Gy, and 54 Gy, respectively, in 28-33 fractions. The prescribed dose is the minimum absorbed dose received by 95% of the planning target volume. 
research content
The 935 patients were divided into normal LDL-C (#3.64 mmol/L; n=816) and elevated LDL-C (.3.64 mmol/L; n=119) groups. The prognostic influence of pretreatment LDL-C levels on clinical outcomes was compared between groups.
statistical analysis
Categorical variables between the two LDL-C groups were compared using the χ 2 test. The Kaplan-Meier method was employed to determine the rates of overall survival (OS), LC, OncoTargets and Therapy 2016:9 submit your manuscript | www.dovepress.com
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lDl-c levels and prognosis in nasopharyngeal carcinoma patients and DM-free survival (DMFS). Survival curves were compared using the log-rank test. The prognostic significance of dif ferent factors was determined using Cox proportional hazards regression models. A statistically significant effect was defined as a P-value ,0.05. All statistical analyses were performed using SPSS 19.0 (IBM Corporation, Armonk, NY, USA).
Results
Follow-up results
The follow-up deadline was May 15, 2015 . The median patient follow-up interval was 61 months (range: 5-88 months). Forty-six patients were lost to follow-up, yielding a follow-up rate of 95.1%; 726 patients were followed up for more than 5 years.
survival status
Of the 935 patients in this study, 83 (8.9%) developed locoregional failure and 119 (12.7%) developed DM. The 5-year OS, LC, and DMFS rates of the entire patient cohort were 87.1%, 91.1%, and 87.2%, respectively. The 5-year OS, LC, and DMFS rates of patients with normal versus elevated LDL-C levels were 77.0% vs 89. 
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effect of pretreatment lDl-c levels on prognosis Table 3 .
Discussion
In this study, the effect of pretreatment LDL-C levels on outcomes of patients with NPC was analyzed retrospectively.
The results of this study show that the DMFS, LC, and OS rates of patients with NPC with normal LDL-C levels were 
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lDl-c levels and prognosis in nasopharyngeal carcinoma patients significantly superior to those of patients with elevated LDL-C before treatment. High pretreatment LDL-C was an independent prognostic factor for reduced DMFS, poorer LC, and lower OS in patients with NPC, suggesting the potential value of LDL-C as a prognostic indicator of clinical outcomes in NPC patients. We did not identify correlations between abnormal HDL-C, total cholesterol, triglycerides, or apolipoprotein A-I levels and prognosis. Furthermore, our results indicate that, in addition to the T stage, N stage, age, and sex, LDL-C is an independent risk factor for poorer OS, LC, and DMFS rates. Although the exact cause is unclear, this is an interesting finding from an oncological perspective. Cholesterol is an essential structural component of the cell membrane, 15 and studies suggest that lipids promote tumor growth, 16 produce energy, and maintain redox homeostasis. 17 Increasing evidence supports the idea that tumor cell growth is partly dependent on exogenous LDL. 18, 19 Low-density lipoprotein receptors (LDLRs) are overexpressed in cancer cells, [20] [21] [22] and this has been attributed to the large quantities of cholesterol and fatty acids that are required for supporting the rapid proliferation that occurs during tumorigenesis in a variety of tumor cells. 21, 23 LDL exposure induces cell proliferation, migration, and loss of adhesion, and is a hallmark of epithelial-to-mesenchymal transition. 24 Scoles et al observed that treatment with oxidized LDL significantly reduced the chemosensitivity of 
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Tang et al both platinum-sensitive CAOV3 and platinum-resistant SKOV3 cells. 19 From these reports, it can be deduced that high LDL-C levels are likely to promote the survival of NPC cells by stimulating tumor cells, thus affecting the sensitivity of chemotherapy, resulting in a poor LC rate.
The interaction between vascular endothelial cells and tumor cells is an important step in tumor metastasis. When tumor cells enter blood vessels, some of the cells rapidly disappear in the circulatory system and other cells quickly establish a position in the blood vasculature, and migrate through the blood vessel wall into the surrounding tissue to form new colonies. The first step in this process, adhesion to vascular endothelial cells, is achieved by tumor surface adhesion molecules such as integrins, endothelial cell adhesion molecules, and vascular cell adhesion molecule-1. In human endothelial cells, LDL can induce a significant increase in the expression of a number of adhesion-related markers, including intercellular adhesion molecule-1, 25 vascular adhesion molecule-1, 26 and P-selectin. 27 Pulawski et al 28 demonstrated that single LDL apheresis significantly lowered plasma concentrations of soluble vascular cell adhesion molecule-1, soluble intercellular adhesion molecule-1, and P-selectin. This suggests that high LDL levels may enhance the adhesiveness of vascular endothelial cells, thereby increasing the ability to capture and permit the transit of extravasating tumor cells. More recently, Reverter et al 29 showed that altered cholesterol levels at the trans-Golgi network/endosome boundary triggered syntaxin 6 (Stx6) accumulation in VAMP3, transferrin, and Rab11-positive recycling endosomes, increasing the interaction between Stx6 and VAMP3, and interfering with the recycling of AvB3 and a5b1 integrins and cell migration, possibly in an Stx6-dependent manner. The fine-tuning of cholesterol levels at the trans-Golgi network/recycling endosome boundary together with a subset of cholesterol-sensitive SNARE proteins may regulate cell migration and invasion. In vivo studies showed that breast tumors were larger, more proliferative, and more likely to develop into lung metastases in hypercholesterolemic mice. 13 Although necessary for normal cellular adhesion, integrins can help cancer cells metastasize. Elevated LDL-C levels seem to contribute to integrin movement and transmission in cancer cells, leading to cell migration and invasion. 29 Our study, which compared NPC patients with normal and elevated LDL-C levels, suggests that elevated LDL-C levels may facilitate DM of NPC cells. This provides a theoretical explanation for why the DMFS rate was significantly higher in the elevated LDL-C group in this study.
Our study is limited by its retrospective design and the relatively small sample size of the high LDL-C group. In addition, LDL-C levels alone cannot adequately reflect the status of blood lipids before treatment. Furthermore, statin users with normal LDL-C levels when diagnosed with NPC may have additional comorbidities that influence survival. Moreover, diversity of the treatment modality and chemotherapy may affect the clinical outcome. However, these data demonstrate the prognostic impact and clinical significance of pretreatment LDL-C levels in patients with NPC, and reducing the level of pretreatment LDL-C may improve the LC rate and reduce DM of NPC. Further prospective studies should be under way to investigate the effect of statins on the prognosis of patients with NPC with high LDL-C by detecting changes in serum LDL-C levels.
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